The previous articles in this supplement have outlined the role of the lung cancer nurse specialist in delivering high quality care for patients with advanced ALK-positive non-small cell lung cancer from investigations and diagnosis through to treatment and toxicity management. This third, and final, article suggests ways of maximising adherence to ceritinib so that patients can achieve the best possible treatment outcome
Cancer Nursing Practice. 15, 10, 34-37. doi: 10.7748/cnp.2016.e1364d
CorrespondenceDiana.Borthwick@nhslothian.scot.nhs.uk
Peer reviewThis article has been subject to external double-blind peer review and checked for plagiarism using automated software
Conflict of interestThis supplement has been commissioned and paid for by Novartis. Novartis has funded medical writing support through Nyxeon Healthcare Communications and payment to the journal for advertorial space. All authors contributed equally to the development, design and review of this article; Novartis has reviewed and approved the content
Received: 30 September 2016
Accepted: 07 November 2016
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
